Gene: FCGR3A

2214
CD16|CD16A|FCG3|FCGR3|FCGRIII|FCR-10|FCRIII|FCRIIIA|IGFR3|IMD20
Fc fragment of IgG receptor IIIa
protein-coding
1q23.3
Ensembl:ENSG00000203747 MIM:146740 Vega:OTTHUMG00000034466 UniprotKB:P08637
NG_009066.1
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.080e-1 (AD)  6.196e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FCER1G0.947
C1QC0.946
HCK0.945
C1QB0.945
ITGB20.94
FCGR2A0.936
C1QA0.936
CD300A0.932
LAPTM50.931
LAT20.93

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KCNIP3-0.513
ZSCAN1-0.486
HES5-0.483
WNT7A-0.478
MARCH4-0.474
CPLX3-0.473
NEUROD6-0.457
ATP2C2-0.455
MAGIX-0.45
ADRA1D-0.447

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00002CetuximabBiotechDrug205923-56-4ApprovedTarget
DB00005EtanerceptBiotechDrug185243-69-0Approved|InvestigationalTarget
DB00028Immune Globulin HumanBiotechDrug9007-83-4Approved|InvestigationalTarget
DB00051AdalimumabBiotechDrug331731-18-1ApprovedTarget
DB00054AbciximabBiotechDrug143653-53-6ApprovedTarget
DB00056Gemtuzumab ozogamicinBiotechDrug220578-59-6Approved|InvestigationalTarget
DB00072TrastuzumabBiotechDrug180288-69-1Approved|InvestigationalTarget
DB00073RituximabBiotechDrug174722-31-7ApprovedTarget
DB00074BasiliximabBiotechDrug179045-86-4Approved|InvestigationalTarget
DB00075MuromonabBiotechDrug140608-64-6Approved|InvestigationalTarget
DB00078Ibritumomab tiuxetanBiotechDrug206181-63-7Approved|InvestigationalTarget
DB00081TositumomabBiotechDrug208921-02-2Approved|InvestigationalTarget
DB00087AlemtuzumabBiotechDrug216503-57-0Approved|InvestigationalTarget
DB00092AlefaceptBiotechDrug222535-22-0Approved|Investigational|WithdrawnTarget
DB00095EfalizumabBiotechDrug214745-43-4Approved|InvestigationalTarget
DB00108NatalizumabBiotechDrug189261-10-7Approved|InvestigationalTarget
DB00110PalivizumabBiotechDrug188039-54-5Approved|InvestigationalTarget
DB00111DaclizumabBiotechDrug152923-56-3Investigational|WithdrawnTarget
DB00112BevacizumabBiotechDrug216974-75-3Approved|InvestigationalTarget
DB06607CatumaxomabBiotechDrug509077-98-9Approved|Investigational|WithdrawnTarget
DB11767SarilumabBiotechDrug1189541-98-7Approved|InvestigationalTarget
DB12023BenralizumabBiotechDrug1044511-01-4Approved|InvestigationalTarget
ID Drug Name Action PubMed
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of FCGR3A mRNA"21346803
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of FCGR3A mRNA"25380136
C0352074-amino-2,6-dinitrotoluene"4-amino-2,6-dinitrotoluene affects the expression of FCGR3A mRNA"21346803
C0415944-nonylphenol[4-tert-octylphenol co-treated with 4-nonylphenol] results in increased expression of FCGR3A mRNA23626723
C1052604-tert-octylphenol[4-tert-octylphenol co-treated with 4-nonylphenol] results in increased expression of FCGR3A mRNA23626723
D000395Air Pollutants, Occupational"Air Pollutants, Occupational results in decreased expression of FCGR3A mRNA"23195993
C000228aristolochic acid I[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of FCGR3A mRNA23912714
C042310aristolochic acid II[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of FCGR3A mRNA23912714
C006632arsenic trioxidearsenic trioxide results in increased expression of FCGR3A mRNA20458559
D001372Aza CompoundsAza Compounds results in decreased expression of FCGR3A mRNA20521778
D001372Aza CompoundsAza Compounds results in increased expression of FCGR3A mRNA20521778
C547126AZM551248AZM551248 results in increased expression of FCGR3A mRNA22323515
C006780bisphenol Abisphenol A results in decreased expression of FCGR3A mRNA25181051
D019256Cadmium ChlorideCadmium Chloride results in increased expression of FCGR3A mRNA25993096
D002509CephaloridineCephaloridine results in increased expression of FCGR3A mRNA18500788
D003471CuprizoneCuprizone results in increased expression of FCGR3A mRNA26577399|2752363
D003474CurcuminCurcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of FCGR3A mRNA]18200517
C014347decitabinedecitabine inhibits the reaction [Smoke results in decreased expression of FCGR3A mRNA]21095227
D002945CisplatinCisplatin results in decreased expression of FCGR3A mRNA22023808
D004041Dietary FatsDietary Fats affects the expression of FCGR3A mRNA19680557
D002117CalcitriolCalcitriol results in decreased expression of FCGR3A mRNA26485663
D004128DimethylnitrosamineDimethylnitrosamine results in increased expression of FCGR3A mRNA25380136
D004317DoxorubicinDoxorubicin results in decreased expression of FCGR3A protein17852453
D005839GentamicinsGentamicins results in increased expression of FCGR3A mRNA22061828
D017313FenretinideFenretinide results in increased expression of FCGR3A mRNA28973697
D007211IndolesIndoles results in decreased expression of FCGR3A mRNA20521778
D007211IndolesIndoles results in increased expression of FCGR3A mRNA20521778
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of FCGR3A mRNA23086925
D015122MercaptopurineMercaptopurine results in increased expression of FCGR3A mRNA23358152
D008628MercuryMercury results in decreased expression of FCGR3A mRNA16823088
D009532NickelNickel results in decreased expression of FCGR3A mRNA23195993
C028007nickel monoxidenickel monoxide results in increased expression of FCGR3A mRNA19167457
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of FCGR3A mRNA25729387
C030110oxaliplatinoxaliplatin results in increased expression of FCGR3A mRNA25729387
D000073878Palm OilPalm Oil affects the expression of FCGR3A mRNA19680557
D010426Pentosan Sulfuric PolyesterPentosan Sulfuric Polyester results in increased expression of FCGR3A mRNA28973697
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of FCGR3A mRNA26794494
D011374ProgesteroneProgesterone results in increased expression of FCGR3A mRNA21540246
D012906Smokedecitabine inhibits the reaction [Smoke results in decreased expression of FCGR3A mRNA]21095227
C013698tallowtallow affects the expression of FCGR3A mRNA19680557
D013853ThioacetamideThioacetamide results in decreased expression of FCGR3A mRNA23411599
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased expression of FCGR3A mRNA25447457
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of FCGR3A mRNA25729387
D019772TopotecanTopotecan results in increased expression of FCGR3A mRNA25729387
D014212TretinoinTretinoin results in increased expression of FCGR3A protein7579340
D014302Trinitrobenzenesulfonic AcidCurcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of FCGR3A mRNA]18200517
D014302Trinitrobenzenesulfonic AcidTrinitrobenzenesulfonic Acid results in increased expression of FCGR3A mRNA18200517
D014800VitalliumVitallium analog results in decreased expression of FCGR3A mRNA23825117
D015039ZiramZiram results in decreased expression of FCGR3A protein18670896

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0019864IgG binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006955immune response-TAS2138330  
GO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis-TAS-  
GO:0050776regulation of immune response-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0009897external side of plasma membrane-IDA10706735  24942581  
GO:0016021integral component of membrane-IEA-  
GO:0070062extracellular exosome-HDA23533145  
KEGG ID KEGG Term
hsa04145Phagosome
hsa04380Osteoclast differentiation
hsa04650Natural killer cell mediated cytotoxicity
hsa04666Fc gamma R-mediated phagocytosis
hsa05140Leishmaniasis
hsa05150Staphylococcus aureus infection
hsa05322Systemic lupus erythematosus
Reactome ID Reactome Term Evidence
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168249Innate Immune SystemTAS
R-HSA-168249Innate Immune SystemIEA
R-HSA-168256Immune SystemTAS
R-HSA-168256Immune SystemIEA
R-HSA-198933Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cellTAS
R-HSA-2029480Fcgamma receptor (FCGR) dependent phagocytosisTAS
R-HSA-2029480Fcgamma receptor (FCGR) dependent phagocytosisIEA
R-HSA-2029481FCGR activationIEA
R-HSA-2029481FCGR activationTAS
R-HSA-2029482Regulation of actin dynamics for phagocytic cup formationTAS
R-HSA-2029485Role of phospholipids in phagocytosisTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25830914Transcriptome analysis in patients with chronic kidney disease on hemodialysis disclosing a key role for CD16+CX3CR1+ monocytes. (2015)Schepers EPLoS One
20439936SNPs of Fc-gamma receptor genes and chronic periodontitis. (2010 Jul)Chai LJ Dent Res